Business Context and Reporting Period
Company: Quoin Pharmaceuticals, Ltd.
Filing Type: Form 8-K (Current Report)
Date of Report: January 20, 2026
Principal Executive Offices: Ashburn, VA
Trading Symbol: QNRX (Nasdaq)
This filing reports a significant regulatory milestone regarding the Company's lead investigational product, QRX003, a topical treatment for Netherton Syndrome.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This is a current report focused on a specific corporate event rather than a periodic financial statement.
Capital Structure Update: As of January 20, 2026, the Company had 1,616,179 American Depositary Shares (ADSs) outstanding, with each ADS representing 35 ordinary shares.
Material Changes and Events
- Regulatory Filing: Quoin filed an application for Breakthrough Medicine Designation with the Saudi Food and Drug Authority (SFDA) for QRX003.
- Product Status: QRX003 is a late-stage topical product candidate for Netherton Syndrome. It has previously received Orphan Drug and Pediatric Rare Disease Designations from the U.S. FDA and Orphan Drug Designation from the European Medicines Agency.
- Commercial Partnership: The Company has an established distribution partnership with Genpharm for QRX003 in Saudi Arabia and other MENA countries.
Guidance, Outlook, and Risks
Management Commentary and Timeline
- Clinical Trials: QRX003 lotion (4%) is being evaluated in two late-stage whole-body pivotal clinical trials. Enrollment is expected to be completed in the first half of 2026.
- Data Readout: Top-line data from these trials is anticipated in the second half of 2026.
- Regulatory Submission: The Company plans to submit a New Drug Application (NDA) in the United States and other territories in late 2026/early 2027, subject to successful clinical outcomes.
- Saudi Arabia Access: If the SFDA Breakthrough Medicine Designation is granted, it could enable earlier patient access in Saudi Arabia, potentially as early as the second half of 2026.
Risks and Contingencies
The filing includes a cautionary note regarding forward-looking statements. Key risks include:
- Failure to deliver a safe and effective treatment for Netherton Syndrome.
- Inability to obtain regulatory approvals or comply with ongoing requirements.
- Delays in completing clinical trials or failure to achieve desired results.
- Unanticipated or higher-than-expected clinical trial costs.
- Inability to obtain necessary capital to fund activities.
Investor Verification Checklist
- Verify the official status of the SFDA Breakthrough Medicine Designation application for QRX003.
- Monitor the progress of enrollment in the two late-stage pivotal clinical trials for completion in H1 2026.
- Confirm the timeline for top-line data release in H2 2026.
- Review the terms of the distribution partnership with Genpharm for the MENA region.
- Assess the Company's cash runway and capital raising plans to support the anticipated NDA submission in late 2026/early 2027.